NGM BIOPHARMACEUTICALS INC Uncategorized Contracts & Agreements

13 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Offer Letter and Arbitration Agreement, by and between the Registrant and Jean-Frdric Viret, Ph.D., dated as of October 20, 2023
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
HI
2024
Offer Letter Agreement, by and between the Registrant and Valerie L. Pierce, dated as of August 6, 2019, and related information
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2024
Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2024
Offer Letter and Arbitration Agreement, by and between the Registrant and Jean-Frdric Viret, Ph.D., dated as of October 20, 2023
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
HI
2023
Amendment No. 1 to Open Market Sale AgreementSM, dated June 7, 2023, between the Company and Jefferies
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
NY
2023
Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2023
Amendment No. 9 on November
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2022
Offer Letter Agreement, by and between the Registrant and Valerie L. Pierce, dated as of August 6, 2019, and related information
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2021
Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2021
Letter Agreement, dated as of March 12, 2021, by and between Merck Sharp & Dohme Corp. and NGM Biopharmaceuticals, Inc
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2021
Offer Letter Agreement, by and between the Registrant and Siobhan Nolan Mangini, dated as of May 20, 2020
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2020
Letter Agreement, by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., dated as of March 15, 2019
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
2019
Letter Agreement, by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., dated as of March 20, 2015
NGM BIOPHARMACEUTICALS INC
Pharmaceuticals
CA
2018